JPWO2019150305A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019150305A5 JPWO2019150305A5 JP2020542110A JP2020542110A JPWO2019150305A5 JP WO2019150305 A5 JPWO2019150305 A5 JP WO2019150305A5 JP 2020542110 A JP2020542110 A JP 2020542110A JP 2020542110 A JP2020542110 A JP 2020542110A JP WO2019150305 A5 JPWO2019150305 A5 JP WO2019150305A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutant
- pharmaceutical composition
- patient
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (8)
- ヒトにおける異常な細胞増殖を治療するための、請求項27に記載の医薬組成物。
- 異常な細胞増殖がガンである、請求項29に記載の医薬組成物。
- ガンが、肺ガン、骨ガン、膵臓ガン、皮膚ガン、頭頚部ガン、皮膚もしくは眼球内黒色腫、子宮ガン、卵巣ガン、直腸ガン、肛門部ガン、胃ガン、結腸ガン、乳ガン、子宮ガン、卵管ガン、子宮内膜ガン、頸ガン、膣ガン、外陰ガン、ホジキン病、食道ガン、小腸ガン、内分泌系ガン、甲状腺ガン、副甲状腺ガン、副腎ガン、軟部組織肉腫、尿道ガン、陰茎ガン、前立腺ガン、慢性もしくは急性白血病、リンパ球性リンパ腫、膀胱ガン、腎臓もしくは尿管のガン、腎細胞ガン、腎孟ガン、中枢神経系(CNS)腫瘍、中枢神経系原発リンパ腫、脊髄軸腫瘍、脳幹グリオーマ、又は下垂体腺腫である、請求項30に記載の医薬組成物。
- ガンが、肺ガン、結腸ガン、膵臓ガン、及び卵巣ガンである、請求項30に記載の医薬組成物。
- ガンがKRAS突然変異体と関係している、請求項30の医薬組成物または請求項34に記載の使用。
- 前記突然変異体がG12C突然変異体である、請求項37に記載の医薬組成物または使用。
- ガンの治療を必要とする患者においてガンを治療するための方法に使用するための医薬であって、該方法は、
(a)ガンがKRAS突然変異体と関係していることを確認すること;及び
(b)治療学的に有効な量の請求項1~26のいずれか一項に記載の化合物もしくはそれらの医薬的に許容できる塩を患者に投与すること;
を含み、医薬は請求項1~26のいずれか一項に記載の化合物もしくはそれらの医薬的に許容できる塩を含む、前記医薬。 - 前記突然変異体がG12C突然変異体である、請求項39に記載の医薬。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624829P | 2018-02-01 | 2018-02-01 | |
US62/624,829 | 2018-02-01 | ||
US201862685383P | 2018-06-15 | 2018-06-15 | |
US62/685,383 | 2018-06-15 | ||
US201962795062P | 2019-01-22 | 2019-01-22 | |
US62/795,062 | 2019-01-22 | ||
PCT/IB2019/050795 WO2019150305A1 (en) | 2018-02-01 | 2019-01-31 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021512131A JP2021512131A (ja) | 2021-05-13 |
JPWO2019150305A5 true JPWO2019150305A5 (ja) | 2022-02-08 |
JP7317028B2 JP7317028B2 (ja) | 2023-07-28 |
Family
ID=65685851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020542110A Active JP7317028B2 (ja) | 2018-02-01 | 2019-01-31 | 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10662204B2 (ja) |
EP (1) | EP3746435B1 (ja) |
JP (1) | JP7317028B2 (ja) |
CA (1) | CA3089936C (ja) |
ES (1) | ES2926373T3 (ja) |
TW (1) | TW201942115A (ja) |
UY (1) | UY38070A (ja) |
WO (1) | WO2019150305A1 (ja) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017266911B2 (en) | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
JP7322019B2 (ja) | 2017-11-15 | 2023-08-07 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
MY196726A (en) | 2018-11-09 | 2023-05-03 | Hoffmann La Roche | Fused ring compounds |
JP7572958B2 (ja) | 2019-02-12 | 2024-10-24 | ノバルティス アーゲー | Tno155及びkrasg12c阻害剤を含む医薬組合せ |
CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
US20220363681A1 (en) * | 2019-08-16 | 2022-11-17 | Genfleet Therapeutics (Shanghai) Inc. | Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof |
CN112390796B (zh) * | 2019-08-19 | 2023-06-27 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
CN112694475A (zh) * | 2019-10-23 | 2021-04-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
US11566007B2 (en) | 2019-11-04 | 2023-01-31 | Revolution Medicines, Inc. | Ras inhibitors |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
CN112851663B (zh) * | 2019-11-12 | 2023-07-18 | 博瑞生物医药(苏州)股份有限公司 | 一种并杂环化合物及其用途 |
EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
JP7480298B2 (ja) * | 2019-12-02 | 2024-05-09 | シャンハイ インリー ファーマシューティカル カンパニー リミテッド | 酸素含有複素環化合物、その製造方法及び使用 |
JP2023504623A (ja) * | 2019-12-04 | 2023-02-06 | アーカス バイオサイエンシーズ,インコーポレーテッド | Hif-2アルファの阻害剤 |
CN113024544B (zh) * | 2019-12-09 | 2024-07-02 | 武汉誉祥医药科技有限公司 | 一种含氰基并杂环化合物及其用途 |
BR112022014635A2 (pt) | 2020-01-28 | 2022-10-11 | Protego Biopharma Inc | Compostos, composições e métodos para estabilizar transtirretina e inibir mau dobramento de transtirretina |
WO2021169990A1 (zh) * | 2020-02-24 | 2021-09-02 | 泰励生物科技(上海)有限公司 | 用于癌症治疗的kras抑制剂 |
AU2021240068A1 (en) | 2020-03-19 | 2022-09-08 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
WO2021210970A1 (en) * | 2020-04-17 | 2021-10-21 | Dong-A St Co., Ltd. | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators |
CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022152313A1 (zh) * | 2021-01-18 | 2022-07-21 | 成都百裕制药股份有限公司 | 嘧啶衍生物及其在医药上的应用 |
CN113072480B (zh) * | 2021-04-13 | 2022-09-30 | 常州佳德医药科技有限公司 | 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用 |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ras抑制劑 |
BR112023024906A2 (pt) * | 2021-05-28 | 2024-02-15 | Redx Pharma Plc | Compostos |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
WO2023009585A2 (en) | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
JP2024532374A (ja) | 2021-09-01 | 2024-09-05 | ノバルティス アーゲー | Tead阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用 |
EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
JP2024537824A (ja) * | 2021-10-01 | 2024-10-16 | インサイト・コーポレイション | ピラゾロキノリンkras阻害剤 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
MX2024004444A (es) | 2021-10-14 | 2024-05-08 | Incyte Corp | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023154124A1 (en) * | 2022-02-09 | 2023-08-17 | Enliven Therapeutics, Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024006379A1 (en) * | 2022-06-30 | 2024-01-04 | Axonis Therapeutics, Inc. | Methods and compounds for inhibiting mkk7 enzymes |
WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶KRas抑制劑 |
WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
RU2586885C2 (ru) | 2011-11-17 | 2016-06-10 | Пфайзер Инк. | Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство |
CN106488910B (zh) * | 2013-10-10 | 2020-07-31 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017015562A1 (en) * | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
AU2017266911B2 (en) * | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
-
2019
- 2019-01-29 TW TW108103302A patent/TW201942115A/zh unknown
- 2019-01-31 US US16/263,185 patent/US10662204B2/en active Active
- 2019-01-31 ES ES19709113T patent/ES2926373T3/es active Active
- 2019-01-31 JP JP2020542110A patent/JP7317028B2/ja active Active
- 2019-01-31 CA CA3089936A patent/CA3089936C/en active Active
- 2019-01-31 UY UY38070A patent/UY38070A/es not_active Application Discontinuation
- 2019-01-31 EP EP19709113.5A patent/EP3746435B1/en active Active
- 2019-01-31 WO PCT/IB2019/050795 patent/WO2019150305A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2019150305A5 (ja) | ||
JP2007530526A5 (ja) | ||
RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
RU2008122471A (ru) | Способ лечения аномального роста клеток | |
JP2020143134A5 (ja) | ||
RU2014124005A (ru) | Комбинация инотузумаба озогамицина и торизела для лечения рака | |
RU2005128791A (ru) | Лекарственные формы, содержащие ag013736 | |
RU2010121647A (ru) | Полиморфы ингибитора c-met/hgfr | |
JP2020105190A5 (ja) | ||
JP2015232006A5 (ja) | ||
JP2008521928A5 (ja) | ||
RU2011148521A (ru) | Соль авт-263 и ее формы в твердом состоянии | |
JP2013505249A5 (ja) | ||
Leitao et al. | Recurrent cervical cancer | |
JP2008534637A5 (ja) | ||
Kang et al. | A stercoral perforation of the descending colon | |
JP2020527139A5 (ja) | ||
RU2014142057A (ru) | Комплексная терапия | |
JP2019527231A5 (ja) | ||
EP3487492A1 (en) | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer | |
JP2021105005A5 (ja) | ||
JPWO2019175776A5 (ja) | ||
JPWO2019209896A5 (ja) | ||
WO2013190273A1 (en) | Therapeutic composition | |
JP2014005265A5 (ja) |